Abstract: The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.
Type:
Application
Filed:
January 2, 2015
Publication date:
April 30, 2015
Applicant:
Symbiotec Genellschaft zur Erforshung auf dem Geibeit der Biotechnologie, MBH